KIT and mastocytosis: Clinical data from single case reports and small series of patients with mastocytosis treated with imatinib led the U.S. Food and Drug Administration (FDA), but not the European Medicines Agency (EMA), to approve the drug in 2006 for adult patients with ASM without the D816V KIT mutation or with unknown or unavailable KIT mutational status.